Arrowhead Pharmaceuticals (ARWR) Intangibles (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Intangibles came in at $6.0 million in Q1 2026, down 22.05% YoY from $7.7 million in Q1 2025, and down 6.6% on a QoQ basis from $6.4 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Intangibles (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Intangibles data on file, last reported at $6.0 million in Q1 2026.
- Quarterly Intangibles fell 22.05% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (down 22.05% YoY) and the FY2025 annual result came in at $6.9 million, down 19.87% from the prior year.
- Intangibles fell to $6.0 million in Q1 2026, from $6.4 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $12.8 million in Q1 2022 to a low of $6.0 million in Q1 2026.
- A 5-year average of $9.4 million and a median of $9.4 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2022 — Intangibles decreased 11.71% — and 2026, when it decreased 22.05%.
- Tracing ARWR's Intangibles over 5 years: stood at $11.5 million in 2022, then decreased by 14.74% to $9.8 million in 2023, then dropped by 17.28% to $8.1 million in 2024, then decreased by 20.9% to $6.4 million in 2025, then fell by 6.6% to $6.0 million in 2026.
- The last three Intangibles figures came in at $6.0 million (Q1 2026), $6.4 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 5.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.59 Mn |
| Mar 31, 2026 | 6.01 Mn |
| Dec 31, 2025 | 6.44 Mn |
| Sep 30, 2025 | 6.86 Mn |
| Jun 30, 2025 | 7.29 Mn |
| Mar 31, 2025 | 7.71 Mn |
| Dec 31, 2024 | 8.14 Mn |
| Sep 30, 2024 | 8.56 Mn |
| Jun 30, 2024 | 8.99 Mn |
| Mar 31, 2024 | 9.41 Mn |
| Dec 31, 2023 | 9.84 Mn |
| Sep 30, 2023 | 10.26 Mn |
| Jun 30, 2023 | 10.69 Mn |
| Mar 31, 2023 | 11.11 Mn |
| Dec 31, 2022 | 11.54 Mn |
| Sep 30, 2022 | 11.96 Mn |
| Jun 30, 2022 | 12.39 Mn |
| Mar 31, 2022 | 12.81 Mn |
| Dec 31, 2021 | 13.24 Mn |
| Sep 30, 2021 | 13.66 Mn |